Title:
移植片対宿主病を処置し予防する方法
Document Type and Number:
Japanese Patent JP6712427
Kind Code:
B2
Abstract:
Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
Inventors:
Micros, david
Bird, John, Sea.
Dubovsky, Jason, A.
Mussammy, Natarajan
Johnson, amy, joe
Bird, John, Sea.
Dubovsky, Jason, A.
Mussammy, Natarajan
Johnson, amy, joe
Application Number:
JP2019083275A
Publication Date:
June 24, 2020
Filing Date:
April 24, 2019
Export Citation:
Assignee:
Pharma Cyclics LLC
International Classes:
A61K31/519; A61K39/395; A61P37/06
Domestic Patent References:
| JP2010504324A |
Foreign References:
| WO2013059738A1 |
Other References:
BRUCE D. CHESON. et al.,Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia,Journal of Clinical Oncology,2012年 8月10日,Vol.30, No.23,2820-2822
JENNIFER A. WOYACH. et al.,The B-cell receptor signaling pathway as a therapeutic target in CLL,BLOOD,2012年 8月 9日,Vol.120, No.6,1175-1184
MARTIN F. M. DE ROOIJ. et al.,The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemoine-controlled adhes,BLOOD,2012年 3月15日,Vol.119, No.11,2590-2594
SABINE PONADER. et al.,The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival an,BLOOD,2012年 2月 2日,Vol.119, No.5,1182-1189
ERIC S WINER. et al.,PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies,Expert Opin. Investig. Drugs,2012年 3月,1-7
SARAH E. M. et al.,Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocyti,BLOOD,2011年 6月 9日,Vol.117, No.23,6287-6296
JENNIFER R BROWN. et al.,PCI-32765, the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials,Curr Hematol Malig Rep,2013年 3月,Vol.8, No.1,1-9
LEE A. HONIGBERG. et al.,The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models,PNAS,2010年 6月20日,Vol.107, No.29,13075-13080
MARINA CETKOVIC-CVRLJE AND FATIH M. UCKUN et al.,Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rartionally designed inhibitors p,British Journal of Haematology,2004年 6月29日,Vol.126,821-827
JENNIFER A. WOYACH. et al.,The B-cell receptor signaling pathway as a therapeutic target in CLL,BLOOD,2012年 8月 9日,Vol.120, No.6,1175-1184
MARTIN F. M. DE ROOIJ. et al.,The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemoine-controlled adhes,BLOOD,2012年 3月15日,Vol.119, No.11,2590-2594
SABINE PONADER. et al.,The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival an,BLOOD,2012年 2月 2日,Vol.119, No.5,1182-1189
ERIC S WINER. et al.,PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies,Expert Opin. Investig. Drugs,2012年 3月,1-7
SARAH E. M. et al.,Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocyti,BLOOD,2011年 6月 9日,Vol.117, No.23,6287-6296
JENNIFER R BROWN. et al.,PCI-32765, the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials,Curr Hematol Malig Rep,2013年 3月,Vol.8, No.1,1-9
LEE A. HONIGBERG. et al.,The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models,PNAS,2010年 6月20日,Vol.107, No.29,13075-13080
MARINA CETKOVIC-CVRLJE AND FATIH M. UCKUN et al.,Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rartionally designed inhibitors p,British Journal of Haematology,2004年 6月29日,Vol.126,821-827
Attorney, Agent or Firm:
Kazuhiro Kiyohara